Bionovate Technologies Corp (BIIO) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBionovate Technologies Corp (BIIO) trades at $0.0001. Bionovate Technologies Corp. is a Swiss medical device company focused on developing automated, computer-driven systems for the precise treatment of age spots. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for BIIO: BIIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Bionovate Technologies Corp (BIIO) Healthcare & Pipeline Overview
Bionovate Technologies Corp. is a Switzerland-based medical device enterprise pioneering automated, computer-driven systems for precise age spot treatment. The company targets global distribution to healthcare providers and wellness centers, positioning itself within the specialized aesthetic dermatology market as an affiliate of Human Data AG.
What Is the Investment Thesis for BIIO?
Bionovate Technologies Corp. (BIIO) is positioned within the medical device sector, specifically targeting the aesthetic dermatology market with its automated age spot treatment system. The investment thesis centers on the potential for technological innovation in a niche, yet growing, segment of cosmetic procedures. The company's focus on a computer-driven system for precise treatment could address market demand for efficiency and consistency in aesthetic services, appealing to healthcare providers and wellness centers globally. However, BIIO operates as an OTC Other tier company with a reported market capitalization of $0.00B and a high Beta of 9.91, indicating significant volatility and an early-stage or limited operational profile. The lack of specific financial disclosures and product details presents substantial informational risk. Investors would be evaluating the long-term potential of its core technology and market penetration strategy, while navigating the inherent challenges of an OTC Other listing, including liquidity constraints and disclosure uncertainties.
Based on FMP financials and quantitative analysis
BIIO Key Highlights
Market Capitalization reported as $0.00B, indicating a very early-stage or minimally active company profile.
- Beta of 9.91 suggests extremely high volatility relative to the broader market, reflecting significant price fluctuations.
- The company does not pay a dividend, consistent with its early-stage or growth-focused operational status.
- Operates on the OTC Other tier, signifying the lowest level of OTC market, typically associated with higher risk and less regulatory oversight.
- Affiliated with Human Data AG since October 7, 2020, potentially influencing its operational and strategic direction.
Who Are BIIO's Competitors?
BIIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.56 | -4.26% | 30 5-pillar | |
| HYPD Hyperion DeFi, Inc. | $2.85 | +1.79% | $42.4M | 35 5-pillar |
| SNWV SANUWAVE Health, Inc. | $5.07 | -2.87% | $44.9M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.82 | -4.41% | $48.6M | 32 5-pillar |
| LNSR LENSAR, Inc. | $5.96 | -1.81% | $73.7M | 43 5-pillar |
| APYX Apyx Medical Corporation | $2.46 | +3.80% | $99.8M | 33 5-pillar |
| MXCT MaxCyte, Inc. | $1.51 | +7.86% | $155M | 31 5-pillar |
| INGN Inogen, Inc. | $7.08 | -0.28% | $188M | 37 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIIO's Key Strengths?
Specialized focus on automated age spot treatment, addressing a specific market need.
- Development of a computer-driven system suggests potential for high precision and consistency in treatments.
- Global distribution strategy indicates ambition for broad market reach.
- Affiliation with Human Data AG since 2020 could provide strategic support or resources.
What Are BIIO's Weaknesses?
Operates on the OTC Other tier, implying higher risk and limited investor access.
- Market capitalization of $0.00B suggests a very early stage, minimal operations, or inactive status.
- Disclosure Status is 'Unknown', leading to significant informational opacity for investors.
- High Beta of 9.91 indicates extreme price volatility and potential for substantial capital risk.
What Are the Key Risks for BIIO?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- **Lack of Financial Transparency:** The 'Unknown' disclosure status on the OTC market means investors have no access to financial statements, making it impossible to assess profitability, cash flow, or debt levels, posing significant informational risk.
- **Market Acceptance and Competition:** Despite its specialized focus, Bionovate faces competition from established players with existing aesthetic device portfolios. Gaining market acceptance for a new, automated system requires substantial marketing and clinical validation.
- **Regulatory Hurdles:** Obtaining and maintaining regulatory approvals for medical devices in multiple global markets is a complex, time-consuming, and expensive process, with potential for delays or outright rejections.
- **Operational Funding and Liquidity:** With a $0.00B market cap and OTC Other listing, securing adequate funding for ongoing R&D, manufacturing, and global distribution could be a persistent challenge, potentially leading to dilution or operational stagnation.
- **High Stock Volatility:** A Beta of 9.91 indicates that BIIO's stock price is highly sensitive to market movements, exposing investors to extreme volatility and potential for significant capital loss.
What Are BIIO's Competitive Advantages?
- Proprietary automated, computer-driven system for age spot treatment, potentially offering unique precision and consistency.
- Specialized focus on a specific dermatological condition (age spots), allowing for deep expertise and targeted product development.
- Potential for intellectual property protection (patents) on its unique automation technology, creating barriers to entry.
- Early mover advantage in highly automated, precise age spot treatment systems, if its technology proves superior.
What Does BIIO Do?
Bionovate Technologies Corp. is a medical device enterprise headquartered in Cham, Switzerland, established in 2010. The company's core mission revolves around the development of pioneering automated solutions specifically engineered for the treatment of age spots. Its primary product focus is a sophisticated, computer-driven system designed to precisely target and treat these dermatological blemishes across any area of the human body. This advanced technology aims to offer a consistent and efficient solution for aesthetic practitioners. The firm's strategic plan includes the global distribution of these innovative systems, targeting a diverse clientele comprising healthcare providers, dermatological clinics, and wellness centers seeking to enhance their aesthetic service offerings. Before its current identity, the organization operated under the name MJP International Ltd. The transition to Bionovate Technologies Corp. occurred in December 2017, marking a strategic pivot towards its current specialization in medical aesthetics. Further solidifying its operational structure, Bionovate Technologies Corp. has been an affiliated entity of Human Data AG since October 7, 2020. This affiliation potentially provides synergistic opportunities or operational oversight within a broader corporate framework. The company's dedication to automation in aesthetic medicine positions it within a growing segment of the healthcare industry, aiming to address the increasing demand for non-invasive cosmetic treatments.
What Products and Services Does BIIO Offer?
- Develops automated, computer-driven medical devices.
- Specializes in systems designed for the precise treatment of age spots.
- Aims to target and treat age blemishes on any area of the body.
- Plans global distribution of its medical systems.
- Markets its products to healthcare providers and wellness centers.
- Operates in the medical device sector, specifically aesthetic dermatology.
- Focuses on pioneering innovative solutions for dermatological conditions.
How Does BIIO Make Money?
- Sells proprietary automated age spot treatment systems to healthcare providers.
- Generates revenue through direct sales of its medical devices to clinics and wellness centers globally.
- Potentially offers maintenance or service contracts for its sophisticated computer-driven systems.
- Focuses on a B2B (business-to-business) model, targeting professional medical and aesthetic practices.
What Industry Does BIIO Operate In?
Bionovate Technologies Corp. operates within the Medical Devices industry, a specialized segment of the broader Healthcare sector. Its focus on automated solutions for age spot treatment places it squarely in the aesthetic dermatology market, which is experiencing sustained growth driven by increasing consumer demand for non-invasive cosmetic procedures. This market is characterized by continuous innovation in laser, light, and energy-based devices designed to address various skin concerns, including pigmentation issues like age spots. BIIO's strategy to develop a computer-driven system aims to capitalize on the trend towards precision, automation, and efficiency in clinical settings. The competitive landscape includes established medical device manufacturers with diverse portfolios of aesthetic technologies, as well as smaller, specialized firms. Bionovate Technologies Corp. seeks to carve out a niche by offering a dedicated, automated solution, differentiating itself through its specific focus and technological approach within this competitive environment.
Who Are BIIO's Key Customers?
- Dermatology clinics and practices.
- Medical spas and aesthetic wellness centers.
- General healthcare providers offering cosmetic services.
- Private hospitals with aesthetic departments.
- Global network of professional aesthetic practitioners.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Bionovate Technologies Corp stands at 23.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -30.5%, a gauge of the cash the business throws off relative to its market value.
Company Profile
Bionovate Technologies Corp operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Cham, CH. The company is led by CEO Timothy Jones. BIIO has traded publicly since 2014.
Financial Health
Bionovate Technologies Corp's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BIIO Financials
BIIO Latest News
No recent news available for BIIO.
BIIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BIIO.
Price Targets
Wall Street price target analysis for BIIO.
BIIO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BIIO; grades run from A+ (80-100) to F (below 30).
Leadership: Timothy Jones
CEO
Timothy Jones serves as the Chief Executive Officer of Bionovate Technologies Corp. His leadership is focused on guiding the company's strategic direction in developing and distributing automated medical devices for aesthetic treatments.
Track Record: Under Timothy Jones's leadership, Bionovate Technologies Corp. has continued its mission to pioneer automated solutions for age spot treatment. Key strategic decisions include the ongoing development of its computer-driven system and the pursuit of global distribution channels. Specific milestones or achievements directly attributable to his leadership are not detailed in the provided information.
BIIO OTC Market Information
Bionovate Technologies Corp. (BIIO) trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like the NYSE or NASDAQ, which must meet stringent listing requirements regarding financial health, corporate governance, and disclosure, OTC Other companies have minimal to no reporting requirements. This tier is typically for companies that do not qualify for OTC Pink Current Information, or those with limited public information. It implies a higher degree of risk due to lack of transparency and often reflects companies that are early-stage, distressed, or have limited operations.
- OTC Tier: OTC Other
- **Lack of Transparency:** Unknown disclosure status means investors have no access to financial statements, operational reports, or other critical information, making informed decisions nearly impossible.
- **Extremely Low Liquidity:** A $0.00B market cap and OTC Other listing typically result in minimal trading volume, wide bid-ask spreads, and significant difficulty in buying or selling shares.
- **High Volatility:** A Beta of 9.91 indicates extreme price fluctuations, exposing investors to substantial and unpredictable capital risk.
- **Limited Regulatory Oversight:** OTC Other companies face minimal regulatory scrutiny compared to major exchanges, increasing the potential for fraud or mismanagement.
- **Difficulty in Valuation:** Without financial disclosures, traditional valuation methods are impossible to apply, leaving investors to speculate on the company's true worth.
- Verify any available corporate filings, even if minimal, through state or international corporate registries.
- Search for independent news articles or press releases from reputable sources, if any exist.
- Attempt to contact investor relations (if available) for any direct information, though unlikely for OTC Other.
- Assess the legitimacy of the company's core technology and market claims through independent research.
- Evaluate the background and track record of the management team, if further details can be found.
- Understand the specific regulatory environment for medical devices in Switzerland and target markets.
- Consider the implications of the 'Unknown' disclosure status and the $0.00B market cap on investment viability.
- Clear and consistent communication of business activities and strategic progress, even if not formal disclosures.
- Evidence of product development milestones, such as successful prototypes, clinical trials (if applicable), or regulatory submissions.
- Formation of verifiable partnerships or collaborations with reputable healthcare organizations or distributors.
- A functional and informative corporate website that provides details about the company's technology and team.
- Any verifiable third-party validation or recognition within the medical device or aesthetic industry.
What Investors Ask About Bionovate Technologies Corp (BIIO) — Healthcare
What does Bionovate Technologies Corp do?
Bionovate Technologies Corp. is a medical device company based in Switzerland dedicated to developing advanced, automated solutions for the treatment of age spots.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The market capitalization of $0.00B is a critical data point, implying either a very early-stage company with no significant valuation, or a company with extremely limited trading activity/public float. This heavily influences the interpretation of all other data.
- The 'Unknown' disclosure status for OTC is a major limitation, preventing any deep financial analysis.
- Specific details on product features, clinical trials, or revenue streams are not provided, limiting the depth of operational analysis.
- CEO background and track record are limited to provided name; specific career details are not available.